Umeå universitets logga

umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Cost-effectiveness of a universal HPV-vaccination in Sweden: A probabilistic Markov model in a high coverage setting
Umeå universitet, Medicinska fakulteten, Institutionen för epidemiologi och global hälsa.
2019 (Engelska)Självständigt arbete på avancerad nivå (masterexamen), 10 poäng / 15 hpStudentuppsats (Examensarbete)
Abstract [en]

Background: Human papillomavirus (HPV) vaccine programs targeting preadolescent girls has been implemented successfully in several countries. But the commercially available vaccines have also been shown to have good clinical effect on boys. With a high female coverage, it has been predicted that the boys receive adequate protection through herd immunity. The aim of this study is to explore the benefits and cost-effectiveness of introducing a quadrivalent HPV-vaccination program for both 12-years old girls and boys in Swedish schools.

Method: A lifetime single cohort static Markov model was constructed using Swedish epidemiological-, economical- and demographical data. The model included the potential effect on CIN, cervical-, anal-, oropharyngeal-, vulvar, penile- and vaginal cancer. The outcome of the analysis was the incremental cost per quality-adjusted life-year and the model accounted for both direct- and indirect costs. Single-way, multi-way and probabilistic sensitivity analysis where used to adjust for parameter uncertainty.

Results: In the base-case analysis vaccinating a birth cohort of 12-years boys would cost an additional € 83.576 per QALY. In realistic scenarios where the tenure price is lower than the current list price the estimated ICER ranges between € 39.702 - € 54.644. With an 85% price reduction the intervention has an 62% to 98% probability of being cost-effective.

Conclusion: The results from this health economic analysis indicate that implementing a universal HPV-vaccination in Sweden could be a cost-effective intervention, but only if the tenure price is substantial lower than the current list price.

Ort, förlag, år, upplaga, sidor
2019. , s. 19
Serie
Centre for Public Health Report Series, ISSN 1651-341X ; 2019:32
Nyckelord [en]
HPV-vaccination, Cost-effectiveness, Sweden
Nationell ämneskategori
Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi
Identifikatorer
URN: urn:nbn:se:umu:diva-166061OAI: oai:DiVA.org:umu-166061DiVA, id: diva2:1376663
Utbildningsprogram
Masterprogram i folkhälsovetenskap
Presentation
2019-05-23, Room A311, Caring Sciences Building, Umeå University, Umeå, 09:00 (Engelska)
Handledare
Examinatorer
Tillgänglig från: 2019-12-10 Skapad: 2019-12-10 Senast uppdaterad: 2019-12-10Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Sök vidare i DiVA

Av författaren/redaktören
Sjöberg, André
Av organisationen
Institutionen för epidemiologi och global hälsa
Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologiHälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi

Sök vidare utanför DiVA

GoogleGoogle Scholar

urn-nbn

Altmetricpoäng

urn-nbn
Totalt: 574 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf